Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...
Main Authors: | S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Lippincott, Williams and Wilkins
2015
|
Registos relacionados
-
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
Por: Lorigan, P, et al.
Publicado em: (2014) -
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Por: Dalle, S, et al.
Publicado em: (2021) -
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
Por: M. Hardy-Werbin, et al.
Publicado em: (2018-02-01) -
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Por: Gupta, A, et al.
Publicado em: (2014) -
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Por: Gupta, A, et al.
Publicado em: (2013)